BioCentury
ARTICLE | Clinical News

Somatoprim: Interim Phase Ib data

January 14, 2013 8:00 AM UTC

Interim data from a Phase Ib trial in healthy male volunteers showed that multiple ascending-doses of Somatoprim with and without octreotide led to no serious adverse events. Reported adverse events were generally mild to moderate and transient. The maximum tolerated dose (MTD) was not reached. Aspireo said Somatoprim also dose-dependently reduced hGH levels. Somatoprim is in a Phase IIa trial to treat acromegaly. ...